Page 1205 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1191

Antineoplastic agents, 949. See differences in, by drug, 515t, eslicarbazepine, 417, 433t, 435t
Chemotherapy; specific cancers 517–518, 518t ezogabine (retigabine), 421, 433t
Antiplatelet agents, 619–620, 624t dopamine receptors and their effects, felbamate, 425–426, 433t
aspirin, 619–620 516–517, 517f gabapentin and pregabalin, 420, 433t,
cilostazol, 621 dopaminergic systems, 516 436t
dipyridamole, 621 electroencephalographic effects, 518 lacosamide, 417–418, 433t, 435t
GP IIb/IIIa antagonists, 621 endocrine effects, 518 lamotrigine, 422, 433t, 435t
thienopyridines, 620 psychological effects, 518 levetiracetam, 422–423, 433t, 436t
Antiprotozoal drugs, 917–937 pharmacokinetics of, 516 mephenytoin, ethotoin, and
African trypanosomiasis and other phenothiazine derivative, 513f, 514–515, phenacemide, 419–420
protozoal infections, 932t–933t 515t oxcarbazepine, 417, 433t, 435t
amebiasis, 928–931 pimozide, 514f, 515 perampanel, 423–424, 433t, 437t
amphotericin, 932t, 935 poisoning management for, 1042 phenobarbital, 424, 433t, 436t
benznidazole, 933t, 934 preparations available, 529t phenytoin, 418f, 418–419, 419f,
eflornithine, 931t, 934 thioxanthene derivatives, 513f, 515, 515t 433t, 435t
malaria, 917–928 Antipyretics, OTC, 1123t primidone, 424–425, 425f,
melarsoprol, 931t, 934 Antiretroviral agents, 870–884. See also 433t, 436t
miltefosine, 935 specific types retigabine, 421, 433t, 437t
nifurtimox, 933t, 934–935 drug-drug interactions of two-drug com- rufinamide, 430, 433t, 436t
nitazoxanide, 933–934 binations of, 877t stiripentol, 431, 433t
paromomycin, 932t, 935 entry inhibitors, 882–883 tiagabine, 420–421, 433t, 437t
pentamidine, 931, 932t, 933 fundamentals of, 870 topiramate, 427–428, 433t, 436t
preparations available, 936t integrase strand transfer inhibitors, vigabatrin, 431, 433t, 437t
sodium stibogluconate, 930f, 932t, 933 883–884 zonisamide, 428, 433t, 436t
suramin, 931t, 934 nonnucleoside reverse transcriptase pharmacokinetics of, 411–413, 412f
visceral leishmaniasis drug combinations, inhibitors, 876–879 preparations available, 438t
935 nucleoside and nucleotide reverse structure of, 418f
Antipruritic agents transcriptase inhibitors, toxicology of
doxepin, 1084 870–876, 871t–872t suicidality in, 434
pramoxine, 1084 in pregnancy, 879t teratogenicity in, 434
Antipsychotic agents, 511–524, 528t–529t. protease inhibitors, 879–882 withdrawal in, 434
See also specific agents Antiseborrhea agents, 1084, 1084t Antisense oligonucleotides (ANOs), 2
atypical, 514f, 515, 515t Antiseizure drugs, 409–439, 433t, Antisepsis, 898t
bipolar disorder agents, newer, 529t 435t–437t Antiseptics, 897. See Disinfectants and
butyrophenone derivatives, 514f, 515, chemistry of, 412f antiseptics; specific types
515t clinical pharmacology of, 432–433, 433t Antispasmodics (anticholinergics),
clinical pharmacology of, 518–524 developmental, 435 1101–1102
adverse reactions to, 518t, 521–523 development of, initial, 409–410, 412f Antithrombin (AT), 611, 612, 612f
benefits and limitations in, epilepsy treated with Antithrombotics
523–524 acetazolamide, 432 description of, 621, 622t, 624t
dosage of, 521, 521t benzodiazepines, 432, 437t nitric oxide, 342, 343f
drug choice in, 519–521, 520t generalized seizures treated with, Antithymocyte globulin (ATG), 990
drug combinations in, 521 428–430 Antithyroid drugs, 689–696, 701t
drug interactions in, 523 ethosuximide, 428–429, 433t, 437t adrenoceptor-blocking agents, 696
indications for phensuximide and methsuximide, anion inhibitors, 695
nonpsychiatric, 519 429f basic pharmacology of, 689–692
psychiatric, 518–519 valproic acid and sodium valproate, clinical pharmacology of,
maintenance treatment in, 521 426f, 426–427, 436t 696–700
overdoses of, 523 molecular targets for Graves’ disease treated with, 698
parenteral preparations of, 521 at excitatory, glutamatergic synapse, hyperthyroidism, 698–699. See also
in elderly, 1061–1062 412f Hyperthyroidism
glutamatergic antipsychotics, 515–516 at inhibitory, GABAergic synapse, iodides, 695, 701t
history of, 511–512 412f nontoxic goiter, 700
lithium and other mood stabilizers, partial seizures and generalized tonic- preparations available, 701t
524–528, 529t clonic seizures treated with, radioactive iodine, 695–696, 701t
molindone, 514f, 515 413–421 thioamides, 693–695, 694f, 701t
pharmacodynamics of, 516–518 carbamazepine, 413–417, 415f, 433t, thyroid neoplasms, 700
cardiovascular effects, 518 435t Antitrichogenic agents, 1084–1085